About this Research Topic
With the recent approval of mRNA vaccines for the prevention of COVID-19 by the U.S. Food and Drug Administration and its successful application, we envision the rapid advancement of the modification of RNA in cancer diagnosis, prevention and treatment in the near future. RNA modification includes RNA synthesis and RNA interference. With advanced sequencing techniques, public depository of raw sequencing data, and bioinformatics, a number of RNA-related subjects such as; endogenously produced microRNAs (miRNAs) and non-coding RNAs (ncRNAs), and exogenously introduced small interfering RNAs (siRNAs), short-hairpin RNAs (shRNAs), and CRISPR RNAs, their target genes, and the pathways they involve, have all been reported to form a vast interconnected network system. These subjects are seen in the pathological development, diagnosis, and prognosis of cancers and are therefore potential targets of drug development for cancer treatment.
The purpose of this research topic is to update the basic, translational, and clinical research on the biological and functional roles of RNA modification in various aspects of cancers, such as; cancer pathogenesis, cancer cell proliferation, migration, invasion, metastasis, drug resistance, diagnosis, prognosis, treatment development, as well as novel drug discovery. This topic collection will help broaden our knowledge on RNA modification in combating cancer related diseases.
This Research Topic welcomes original research, case reports, commentaries and review (including meta-analysis and systematic reviews) articles that focus on, but not limited to, the following topics:
- Technology to identify and analyze RNAs and their target genes
- Techniques to deliver siRNA and shRNA into target cells and the off-target effects
- Modification of RNAs in cancer cell proliferation, metastasis and cancer drug resistance
- RNAs in cancer immune regulation, immunotherapy and inflammatory response
- RNAs in cancer diagnosis, prognosis, treatment, and drug development
- RNAs in other aspects of cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The purpose of this research topic is to update the basic, translational, and clinical research on the biological and functional roles of RNA modification in various aspects of cancers, such as; cancer pathogenesis, cancer cell proliferation, migration, invasion, metastasis, drug resistance, diagnosis, prognosis, treatment development, as well as novel drug discovery. This topic collection will help broaden our knowledge on RNA modification in combating cancer related diseases.
This Research Topic welcomes original research, case reports, commentaries and review (including meta-analysis and systematic reviews) articles that focus on, but not limited to, the following topics:
- Technology to identify and analyze RNAs and their target genes
- Techniques to deliver siRNA and shRNA into target cells and the off-target effects
- Modification of RNAs in cancer cell proliferation, metastasis and cancer drug resistance
- RNAs in cancer immune regulation, immunotherapy and inflammatory response
- RNAs in cancer diagnosis, prognosis, treatment, and drug development
- RNAs in other aspects of cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: RNA, pathogenesis, diagnosis, prognosis, cancer, treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
